Status:
COMPLETED
(Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer
Lead Sponsor:
AstraZeneca
Conditions:
Non-Metastatic Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this trial is to study the effect of adjuvant or immediate hormonal therapy, versus placebo, in subjects who have either undergone a primary therapy (principally radical prostatectomy o...
Eligibility Criteria
Inclusion
- Clinical diagnosis of non-metastatic cancer of the prostate gland
- Patient to be 18 years and above
Exclusion
- Previous systemic therapy for prostate cancer
- Previous history of another form of cancer (not prostate) within 5 years of study start.
Key Trial Info
Start Date :
September 1 1995
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2008
Estimated Enrollment :
3588 Patients enrolled
Trial Details
Trial ID
NCT00673205
Start Date
September 1 1995
End Date
August 1 2008
Last Update
December 10 2010
Active Locations (128)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Wooloongabba, Queensland, Australia
2
Research Site
East Melbourne, Victoria, Australia
3
Research Site
Graz, Austria
4
Research Site
Linz, Austria